A virtual meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 2, 2024 with the following interim recommendations made:

• Desloratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 35mg of desloratadine, remain in Schedule III

• Desloratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing no more than 35mg of desloratadine, be granted Unscheduled status

Any objections to these interim recommendations must be received by the NAPRA office by end of day July 10, 2024. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.